BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21704406)

  • 1. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
    Hehlgans S; Lange I; Eke I; Cordes N
    Radiother Oncol; 2009 Sep; 92(3):371-8. PubMed ID: 19729215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
    Hehlgans S; Eke I; Cordes N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
    Güster JD; Weissleder SV; Busch CJ; Kriegs M; Petersen C; Knecht R; Dikomey E; Rieckmann T
    Radiother Oncol; 2014 Dec; 113(3):345-51. PubMed ID: 25467050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
    Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
    Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
    Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
    Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition.
    Eke I; Dickreuter E; Cordes N
    Radiother Oncol; 2012 Aug; 104(2):235-42. PubMed ID: 22748391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
    Rossow L; Eke I; Dickreuter E; Cordes N
    Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells.
    Steglich A; Vehlow A; Eke I; Cordes N
    Cancer Lett; 2015 Feb; 357(2):542-8. PubMed ID: 25497870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.
    Lu H; Liang K; Lu Y; Fan Z
    Cancer Lett; 2012 Sep; 322(1):78-85. PubMed ID: 22348829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
    Golubovskaya VM; Virnig C; Cance WG
    Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.